
ADHD
Latest News
Latest Videos

Shorts









Podcasts
More News

The FDA has approved novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine for ADHD in children, adolescents, and adults

In a recent study, later age at ADHD diagnosis was associated with lower GPA, reduced academic attainment, and greater school dropout rates.

A study found that an FDA-cleared device was safe for pediatric patients with ADHD but did not significantly improve symptoms vs sham treatment.

A study found that children with both a low 5-minute Apgar score and low umbilical cord blood pH at birth had an increased risk of ADHD.

A study found that individuals with ADHD traits in childhood had increased odds of physical multimorbidity and disability by midlife.

FDA accepted centanafadine NDA for priority review, supported by phase 3 trials showing efficacy in children, adolescents, and adults with ADHD.

A large 2026 meta-analysis found no association between prenatal paracetamol (acetaminophen) use and autism, ADHD, or intellectual disability in children.

The investigational compound centanafadine to treat ADHD in children, adults, and adolescents, is a first-in-class NDSRI.

High-dose centanafadine significantly improved ADHD symptoms in children aged 6 to 12 years and was well tolerated, according to findings from a phase 3 clinical trial.

Explore essential resources and toolkits for managing the ongoing stimulant medication shortage affecting ADHD treatment and patient care.

Findings may help guide clinicians and policymakers in balancing the risks and benefits of stimulant prescribing in adolescent populations, according to the study authors.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

"My takeaway is that if medicine is needed, stimulants will be my first choice in this age group, regardless of whether the ADHD coexists with ASD."

Digital therapeutics help kids build emotional regulation and coping skills, supporting pediatric care while waiting for specialized mental health services.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
















